Synopsis: Liver diseases are highly prevalent in the Asia-Pacific region. The region hosts some of the most active key opinion leaders and investigators with strong experience working with biotechnology companies on hepatology trials.
During this brief we will discuss:
Professor Yuen is the Chair Professor and Endowed Professor in Medicine of the Li Shu Fan Medical Foundation, the Chief of the Division of Gastroenterology and Hepatology and the Deputy Chief of Service of the Department of Medicine, Queen Mary Hospital, Hong Kong and the Assistant Dean of the Faculty of Medicine, the University of Hong Kong.
Professor Yuen's research interests include the prevention, natural history, molecular virology and treatment of chronic hepatitis B and C, and hepatocellular carcinoma. He has published more than 420 research papers. Professor Yuen is one of the top authors for publications related to chronic hepatitis B disease in the world.
Professor Jacob George is a renowned hepatologist and liver research scientist who studies the causes of and mechanisms for the development of liver disease and liver cancer. He contributes to investigator-initiated and multicentre international clinical trials on therapeutics for liver diseases, and leads a program of research on viral hepatitis, fatty liver disease, liver fibrosis, host genetics/liver immunology and the epidemiology, prevention and management of liver cancer. He is a Fellow of the American Association for the Study of Liver Disease.
Dr. Gane trained in hepatology at the Institute of Liver Studies, King’s College School of Medicine, London, where he completed his MD on the pathogenesis of hepatitis C-related liver allograft injury following transplantation for HCV-cirrhosis. Dr. Gane is an Investigator for many international clinical trials of therapies for chronic viral hepatitis with particular interest in early phase development of new direct acting antiviral therapies against hepatitis C and hepatitis B. Dr. Gane has published almost 150 papers in peer-reviewed journals including The Lancet and The New England Journal of Medicine and serves on the editorial committee for several journals.
Dr. Hamilton currently serves as Vice President, Clinical Development at Arrowhead Pharmaceuticals and previously served as Medical Director and Head of Corporate Development at Arrowhead. In these roles, he has designed and managed multiple clinical studies with a wide range of siRNA compounds and has led clinical programs in various disease areas including hepatitis B, alpha-1 antitrypsin deficiency and dyslipidemia. Dr. Hamilton holds an MD and an MBA from The Ohio State University and is board certified in Emergency Medicine.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.